

Michael R Zile

List of Publications by Citations

Source: <https://exaly.com/author-pdf/993633/michael-r-zile-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

339
papers

29,616
citations

84
h-index

164
g-index

364
ext. papers

36,779
ext. citations

9.2
avg, IF

7
L-index

#	Paper	IF	Citations
339	Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 993-1004	59.2	3301
338	Irbesartan in patients with heart failure and preserved ejection fraction. <i>New England Journal of Medicine</i> , 2008 , 359, 2456-67	59.2	1307
337	Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. <i>New England Journal of Medicine</i> , 2004 , 350, 1953-9	59.2	1113
336	New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. <i>Circulation</i> , 2002 , 105, 1387-93	16.7	923
335	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1387-95	40	756
334	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	59.2	705
333	New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. <i>Circulation</i> , 2002 , 105, 1503-8	16.7	587
332	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. <i>Circulation</i> , 2016 , 134, 73-90	16.7	485
331	Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 447-56	15.1	439
330	Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. <i>Circulation</i> , 2006 , 114, 397-403	16.7	437
329	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , 2015 , 131, 54-61	16.7	430
328	Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1073-9	15.1	399
327	Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?. <i>Circulation</i> , 2001 , 104, 779-82	16.7	376
326	Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. <i>Circulation</i> , 2015 , 131, 1247-59	16.7	367
325	Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. <i>Circulation</i> , 2008 , 118, 1433-41	16.7	340
324	Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. <i>Circulation</i> , 2006 , 113, 2089-96	16.7	326
323	Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. <i>Circulation</i> , 2011 , 124, 2491-501	16.7	322

322	Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. <i>Circulation Research</i> , 1999 , 85, 364-76	15.7	287
321	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017 , 135, e1054-e1091	16.7	274
320	Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. <i>Lancet, The</i> , 2007 , 369, 2079-87 ⁴⁰		269
319	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2013 , 15, 1062-73	12.3	264
318	Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1733-40	15.1	248
317	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015 , 36, 1990-7	9.5	245
316	The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. <i>Journal of Cardiac Failure</i> , 2005 , 11, 191-5	3.3	245
315	Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. <i>Circulation</i> , 2010 , 121, 1393-405	16.7	241
314	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 377, 41-51	59.2	232
313	Left ventricular diastolic dysfunction and diastolic heart failure. <i>Annual Review of Medicine</i> , 2004 , 55, 373-94	17.4	219
312	Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. <i>Circulation</i> , 2005 , 111, 2306-12	16.7	214
311	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9	213
310	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	201
309	Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. <i>Circulation</i> , 2006 , 113, 296-304	16.7	198
308	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2425-2436	15.1	190
307	Myocardial infarct expansion and matrix metalloproteinase inhibition. <i>Circulation</i> , 2003 , 107, 618-25	16.7	189
306	Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. <i>American Journal of Cardiology</i> , 2007 , 99, 393-8	3	185
305	Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). <i>Circulation: Heart Failure</i> , 2011 , 4, 27-35	7.6	184

304	Cardiac macrophages promote diastolic dysfunction. <i>Journal of Experimental Medicine</i> , 2018 , 215, 423-440	6.6	182
303	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 471-482	7.9	176
302	Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. <i>Circulation: Heart Failure</i> , 2011 , 4, 569-77	7.6	173
301	Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2011 , 4, 324-31	7.6	168
300	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 333-340	18.1	164
299	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 740-51	7.6	159
298	Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. <i>Circulation</i> , 2006 , 114, 1020-7	16.7	159
297	Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. <i>Circulation: Heart Failure</i> , 2011 , 4, 246-56	7.6	154
296	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 1096-103	12.3	150
295	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9, e002763	7.6	147
294	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020 , 141, 352-361	16.7	145
293	Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008 , 10, 149-56	12.3	144
292	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015 , 3, 487-496	7.9	139
291	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 489-498	7.9	138
290	Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3919-30	15.9	138
289	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 535-42	12.3	137
288	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015 , 36, 2576-84	9.5	129
287	Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 571-8	7.6	129

286	Cytoskeletal mechanics in pressure-overload cardiac hypertrophy. <i>Circulation Research</i> , 1997 , 80, 281-9	15.7	126
285	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
284	Membrane-associated matrix proteolysis and heart failure. <i>Circulation Research</i> , 2013 , 112, 195-208	15.7	120
283	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015 , 17, 925-35	12.3	120
282	Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2014 , 16, 817-25	12.3	119
281	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1228-1234	12.3	118
280	Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). <i>Journal of Cardiac Failure</i> , 2007 , 13, 530-40	3.3	116
279	Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 510-7	12.3	115
278	The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. <i>Journal of Cardiac Failure</i> , 2005 , 11, 576-85	3.3	113
277	Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 614-9		110
276	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , 2017 , 38, 1132-1143	9.5	109
275	Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2000 , 32, 109-20	5.8	108
274	Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 288, H149-58	5.2	106
273	Cytoskeletal role in the transition from compensated to decompensated hypertrophy during adult canine left ventricular pressure overloading. <i>Circulation Research</i> , 1998 , 82, 751-61	15.7	106
272	Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. <i>Circulation</i> , 2009 , 119, 269-80	16.7	105
271	Chronic ambulatory intracardiac pressures and future heart failure events. <i>Circulation: Heart Failure</i> , 2010 , 3, 580-7	7.6	102
270	The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. <i>JACC: Cardiovascular Imaging</i> , 2014 , 7, 870-8	8.4	101
269	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). <i>Circulation</i> , 2017 , 135, 724-735	16.7	100

268	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e002744	7.6	100
267	Integrin activation and focal complex formation in cardiac hypertrophy. <i>Journal of Biological Chemistry</i> , 2000 , 275, 35624-30	5.4	100
266	Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H614-22	5.2	98
265	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). <i>Circulation</i> , 2016 , 133, 2254-62	16.7	96
264	Changes in extracellular collagen matrix alter myocardial systolic performance. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003 , 284, H122-32	5.2	92
263	Health-Related Quality of Life Outcomes in PARADIGM-HF. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	91
262	Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. <i>Journal of Cardiac Failure</i> , 2016 , 22, 753-60	3.3	90
261	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 547-554	18.1	89
260	Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. <i>Circulation Research</i> , 2003 , 92, 177-85	15.7	88
259	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016 , 37, 3167-3174	7.4	88
258	Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2059-2071	15.1	87
257	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016 , 1, 666-72	16.2	86
256	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 29-40	15.1	86
255	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2017 , 2, 79-85	16.2	84
254	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 795-806	15.1	82
253	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 241-248	15.1	81
252	Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. <i>Circulation: Heart Failure</i> , 2011 , 4, 561-8	7.6	80
251	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1264-1272	15.1	79

250	Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 152-158	7.9	73
249	Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012 , 143, 656-64	1.5	73
248	Systolic and diastolic mechanics in stress cardiomyopathy. <i>Circulation</i> , 2014 , 129, 1659-67	16.7	72
247	New molecular mechanism in diastolic heart failure. <i>Circulation</i> , 2006 , 113, 1922-5	16.7	72
246	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015 , 373, 2289-90	59.2	71
245	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	7.6	70
244	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 337-341	12.3	69
243	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	68
242	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 129-137	12.3	68
241	Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. <i>Journal of Cardiac Failure</i> , 2011 , 17, 167-78	3.3	67
240	Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation. <i>JACC Basic To Translational Science</i> , 2016 , 1, 14-28	8.7	66
239	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015 , 36, 434-9	9.5	66
238	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2490-2500	15.1	65
237	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019 , 21, 23-36	12.3	64
236	Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. <i>Congestive Heart Failure</i> , 2011 , 17, 248-54		63
235	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015 , 17, 1066-74	12.3	62
234	Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014 , 7, 953-9	7.6	62
233	Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1080-4	15.1	62

232	Myocardial fibroblast-matrix interactions and potential therapeutic targets. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 70, 92-9	5.8	61
231	Microtubule depolymerization normalizes in vivo myocardial contractile function in dogs with pressure-overload left ventricular hypertrophy. <i>Circulation</i> , 2000 , 102, 1045-52	16.7	61
230	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , 2014 , 16, 778-87	12.3	60
229	Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. <i>JACC: Heart Failure</i> , 2014 , 2, 123-30	7.9	60
228	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018 , 15, e1002541	11.6	60
227	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. <i>Circulation</i> , 2015 , 131, 43-53	16.7	58
226	Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 501-15	3.3	58
225	Efficacy of Sacubitril/Valsartan Relative to Prior Decompensation: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 816-822	7.9	58
224	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2018 , 3, 498-505	16.2	57
223	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 671-7	12.3	56
222	Integrating the myocardial matrix into heart failure recognition and management. <i>Circulation Research</i> , 2013 , 113, 725-38	15.7	56
221	Diastolic heart failure: definitions and terminology. <i>Progress in Cardiovascular Diseases</i> , 2005 , 47, 307-13	8.5	56
220	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. <i>American Heart Journal</i> , 2018 , 205, 1-11	4.9	55
219	Role of microtubules in the contractile dysfunction of hypertrophied myocardium. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 250-60	15.1	55
218	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2858-2873	15.1	55
217	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	54
216	Outcomes and Effect of Treatment According to Etiology in HFref: An Analysis of PARADIGM-HF. <i>JACC: Heart Failure</i> , 2019 , 7, 457-465	7.9	54
215	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 3442-51	9.5	54

214	Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , 2018 , 24, 682-694	3.3	54
213	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	53
212	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 1175-82	12.3	53
211	Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 217-25	7.6	51
210	Constitutive properties of adult mammalian cardiac muscle cells. <i>Circulation</i> , 1998 , 98, 567-79	16.7	50
209	Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality. <i>JACC: Heart Failure</i> , 2014 , 2, 512-22	7.9	49
208	Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. <i>American Journal of Cardiology</i> , 2008 , 102, 459-62	3	49
207	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). <i>JACC: Heart Failure</i> , 2015 , 3, 429-441	7.9	48
206	Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1106-13	15.1	48
205	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 42-7	9.5	48
204	Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. <i>Journal of Cardiac Failure</i> , 2010 , 16, 128-34	3.3	47
203	Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. <i>FASEB Journal</i> , 2009 , 23, 2759-71	0.9	47
202	Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H2324-35	5.2	46
201	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , 2015 , 17, 809-17	12.3	45
200	Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. <i>Circulation</i> , 1997 , 95, 1601-10	16.7	45
199	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018 , 20, 760-768	12.3	44
198	In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 295, H314-26	5.2	44
197	Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease. <i>Radiology</i> , 2015 , 275, 80-8	20.5	43

196	HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis. <i>Circulation: Heart Failure</i> , 2015 , 8, 1094-104	7.6	43
195	Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2690-2707	15.1	43
194	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , 2019 , 7, 336-346	7.9	42
193	Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1-13	15.1	41
192	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	7.9	40
191	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 601-612	15.1	40
190	β integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. <i>PLoS ONE</i> , 2012 , 7, e45076	3.7	40
189	Cardiopulmonary exercise variables in diastolic versus systolic heart failure. <i>American Journal of Cardiology</i> , 2008 , 102, 203-6	3	40
188	Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012 , 143, 215-23	1.5	39
187	Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. <i>Circulation: Heart Failure</i> , 2013 , 6, 508-16	7.6	39
186	Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology. <i>Journal of Cardiac Failure</i> , 2011 , 17, 282-91	3.3	39
185	Effect of Praliquat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1522-1531	27.4	39
184	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019 , 8, e013114	6	38
183	Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. <i>Lancet, The</i> , 2021 , 398, 991-1001	40	38
182	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	37
181	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, e004446	7.6	37
180	Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. <i>Journal of Cardiac Failure</i> , 2008 , 14, 816-23	3.3	37
179	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	36

178	Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. <i>European Heart Journal</i> , 2013 , 34, 676-83	9.5	36
177	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006539	7.6	36
176	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	35
175	The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. <i>Drug Safety</i> , 2012 , 35, 233-44	5.1	35
174	Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 303, H234-40	5.2	35
173	Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization. <i>American Journal of Physiology - Cell Physiology</i> , 2015 , 308, C972-82	5.4	34
172	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart</i>	7.6	34
171	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	34
170	Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 302, H1429-37	5.2	34
169	Lack of relationship between Doppler indices of diastolic function and left ventricular pressure transients in patients with definite diastolic heart failure. <i>American Heart Journal</i> , 2004 , 148, E12	4.9	34
168	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1701-1709	12.3	34
167	Age and SPARC change the extracellular matrix composition of the left ventricle. <i>BioMed Research International</i> , 2014 , 2014, 810562	3	33
166	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020 , 13, e006541	7.6	31
165	Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018 , 315, H92-H100	5.2	31
164	Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H1696-706	5.2	31
163	The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , 2019 , 21, 40-49	12.3	31
162	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 974-984	12.3	30
161	Cardiac-specific expression and hypertrophic upregulation of the feline Na(+)-Ca(2+) exchanger gene H1-promoter in a transgenic mouse model. <i>Circulation Research</i> , 2002 , 90, 158-64	15.7	30

160	Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 303, H1128-34	5.2	29
159	STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. <i>International Journal of Biological Sciences</i> , 2008 , 4, 184-99	11.2	29
158	Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016 , 310, E1027-35	6	29
157	Lactosylceramide contributes to mitochondrial dysfunction in diabetes. <i>Journal of Lipid Research</i> , 2016 , 57, 546-62	6.3	29
156	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018 , 138, 2763-2773	16.7	29
155	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , 2019 , 140, 1369-1379	16.7	28
154	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). <i>Circulation</i> ,	16.7	28
153	History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 960-6	7.6	28
152	Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. <i>American Journal of Cardiology</i> , 2011 , 107, 321-4	3	28
151	Heart failure in aortic stenosis - improving diagnosis and treatment. <i>New England Journal of Medicine</i> , 2003 , 348, 1735-6	59.2	28
150	Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. <i>Circulation</i> , 2005 , 112, 3107-14	16.7	28
149	Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2015 , 8, 733-40	7.6	27
148	Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. <i>JACC: Heart Failure</i> , 2020 , 8, 347-358	7.9	27
147	Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. <i>American Journal of Medicine</i> , 2013 , 126, 150-61	2.4	27
146	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 503-514	15.1	27
145	Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. <i>American Journal of Cardiology</i> , 2007 , 99, 460-4	3	26
144	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 169-76	12.3	25
143	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 372-381	7.9	25

142	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017 , 38, 742-750	9.5	25
141	Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. <i>Histochemistry and Cell Biology</i> , 2010 , 134, 23-30	2.4	25
140	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017 , 188, 35-41	4.9	24
139	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <i>American Heart Journal</i> , 2019 , 214, 18-27	4.9	24
138	Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018 , 315, H958-H967	5.3	24
137	Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling. <i>Circulation: Heart Failure</i> , 2012 , 5, 803-11	7.6	24
136	Mitochondrial biogenesis induced by the β -adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. <i>Kidney International</i> , 2019 , 96, 656-673	9.9	23
135	Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. <i>American Journal of Cardiology</i> , 2009 , 104, 1413-5	3	23
134	Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). <i>Circulation</i> , 2008 , 118, 1241-9	16.7	23
133	A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H2231-41	5.2	23
132	Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003 , 285, H1270-85	5.2	23
131	Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. <i>Circulation</i> , 2005 , 112, 300-3	16.7	23
130	From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited. <i>Circulation Research</i> , 2021 , 128, 1451-1467	15.7	23
129	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1861-1871	15.1	22
128	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 432-441	16.2	22
127	The prevalence and importance of frailty in heart failure with reduced ejection fraction: an analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2123-2133	12.3	22
126	Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. <i>FASEB Journal</i> , 2016 , 30, 370-9	0.9	22
125	In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). <i>American Journal of Cardiology</i> , 2012 , 110, 1150-5	3	22

124	A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. <i>Journal of Cardiac Failure</i> , 2004 , 10, 193-9	3.3	22
123	Effect of catheter positioning on the variability of measured gradient in aortic stenosis. <i>Catheterization and Cardiovascular Diagnosis</i> , 1993 , 30, 287-92		22
122	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019 , 21, 577-587	12.3	22
121	Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. <i>Journal of Cardiac Failure</i> , 2011 , 17, 366-73	3.3	21
120	Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. <i>American Heart Journal</i> , 2006 , 152, 246-52	4.9	21
119	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017 , 23, 20-28	3.3	20
118	Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?. <i>JACC: Clinical Electrophysiology</i> , 2017 , 3, 291-298	4.6	20
117	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nepriylsin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2018 , 3, 1226-1234	16.2	20
116	Constitutive properties of hypertrophied myocardium: cellular contribution to changes in myocardial stiffness. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H2173-82	5.3	19
115	Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 669-679	15.1	19
114	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 564-569	7.9	18
113	The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. <i>Journal of Hypertension</i> , 2011 , 29, 1829-36	1.9	18
112	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. <i>JACC: Heart Failure</i> , 2020 , 8, 844-855	7.9	18
111	How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. <i>Journal of Cardiac Failure</i> , 2016 , 22, 283-93	3.3	17
110	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015 , 3, 478-486	7.9	17
109	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1662-1671	12.3	17
108	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. <i>American Journal of Medicine</i> , 2018 , 131, 1473-1481	2.4	17
107	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. <i>American Heart Journal</i> , 2018 , 204, 139-150	4.9	17

106	Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. <i>American Journal of Medicine</i> , 2014 , 127, 132-9	2.4	17
105	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 2018 , 266, 187-192	3.2	16
104	Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. <i>Circulation: Heart Failure</i> , 2014 , 7, 340-50	7.6	16
103	Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates. <i>Hypertension Research</i> , 2015 , 38, 551-9	4.7	16
102	Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2012 , 18, 487-92	3.3	16
101	Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2005 , 11, 124-30	3.3	16
100	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 528-538	12.3	16
99	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018 , 11, e005133	7.6	16
98	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. <i>Circulation: Heart Failure</i> , 2015 , 8, 717-24	7.6	15
97	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 2093-2101	12.3	15
96	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016 , 28, 320-328	1.7	15
95	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019 , 12, e005766	7.6	14
94	Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, F210-F218	4.3	14
93	Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. <i>American Journal of Hypertension</i> , 2013 , 26, 1234-41	2.3	14
92	Chronic heart failure: a report from the Dartmouth Diastole Discourses. <i>Congestive Heart Failure</i> , 2006 , 12, 162-5		14
91	Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 2056-2064	12.3	14
90	Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2019 , 4, 924-937	8.7	14
89	Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. <i>Circulation: Heart Failure</i> , 2020 , 13, e006696	7.6	13

88	Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. <i>Circulation: Heart Failure</i> , 2016 , 9, e002543	7.6	13
87	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1021-31	12.3	13
86	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 3741-3752	9.5	13
85	Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 309, F79-87	4.3	12
84	A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study. <i>Journal of Cardiology</i> , 2015 , 66, 253-62	3	12
83	Mechanisms of cardiac hypertrophy in canine volume overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998 , 275, H65-74	5.2	12
82	Hemodynamic Determinants of Echocardiographically-Derived Indices of Left Ventricular Filling. <i>Echocardiography</i> , 1992 , 9, 289-300	1.5	12
81	The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio. <i>International Journal of Cardiology</i> , 2016 , 215, 521-6	3.2	12
80	Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al. <i>ESC Heart Failure</i> , 2018 , 5, 1069-1071	3.7	12
79	Diastolic Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2000 , 2, 439-450	2.1	11
78	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 418-427	7.9	10
77	Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator pralicigat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). <i>Journal of Cardiology</i> , 2022 , 73, 100-100	4.9	10
76	Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014 , 307, H752-61	5.2	10
75	Left ventricular diastolic function and exercise capacity in community-dwelling adults \geq 5 years of age without heart failure. <i>American Journal of Cardiology</i> , 2011 , 108, 735-40	3	10
74	Left ventricular hypertrophy in a canine model of reversible pressure overload. <i>Cardiovascular Research</i> , 1992 , 26, 580-5	9.9	10
73	Estrogen-Related Receptor α (ERR α) is required for adaptive increases in PGC-1 isoform expression during electrically stimulated contraction of adult cardiomyocytes in sustained hypoxic conditions. <i>International Journal of Cardiology</i> , 2015 , 187, 393-400	3.2	9
72	Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. <i>American Journal of Cardiology</i> , 2019 , 124, 756-762	3	9
71	Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates. <i>Heart and Vessels</i> , 2017 , 32, 1202-1213	2.1	9

70	Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes.. <i>Nature Communications</i> , 2022 , 13, 203	17.4	9
69	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2370-2379	12.3	9
68	Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST). <i>Circulation: Heart Failure</i> , 2015 , 8, 17-24	7.6	8
67	Activation of Inflammatory and Pro-Thrombotic Pathways in Acute Stress Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2017 , 4, 49	5.4	8
66	Diastolic heart failure: diagnosis and treatment. <i>Clinical Cornerstone</i> , 2000 , 3, 13-24		8
65	Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. <i>ESC Heart Failure</i> , 2021 , 8, 1130-1138	3.7	8
64	Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. <i>JAMA Cardiology</i> , 2018 , 3, 1232-1243	16.2	8
63	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1961-1973	15.1	7
62	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1518-1524	12.3	7
61	Elevated Wall Tension Leads to Reduced miR-133a in the Thoracic Aorta by Exosome Release. <i>Journal of the American Heart Association</i> , 2019 , 8, e010332	6	7
60	Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course. <i>Journal of Palliative Medicine</i> , 2017 , 20, 1068-1073	2.2	6
59	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 618-626	7.9	6
58	Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>American Journal of Medicine</i> , 2020 , 133, 1187-1194	2.4	6
57	Renal sympathetic denervation for blood pressure control: a review of the current evidence and ongoing studies. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 331-41	2.3	6
56	In vivo measurements of the contributions of protein synthesis and protein degradation in regulating cardiac pressure overload hypertrophy in the mouse. <i>Molecular and Cellular Biochemistry</i> , 2012 , 367, 205-13	4.2	6
55	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
54	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1358-1365.1		5
53	Pressure overload generates a cardiac-specific profile of inflammatory mediators. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020 , 319, H331-H340	5.2	5

52	Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. <i>Physiological Reports</i> , 2017 , 5, e13462	2.6	5
51	Prediction of worsening heart failure events and all-cause mortality using an individualized risk stratification strategy. <i>ESC Heart Failure</i> , 2020 , 7, 4277	3.7	5
50	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. <i>American Journal of Medicine</i> , 2021 , 134, e252-e263	2.4	5
49	SPARC production by bone marrow-derived cells contributes to myocardial fibrosis in pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021 , 320, H604-H612	5.2	5
48	Changes in Myocardial Microstructure and Mechanics With Progressive Left Ventricular Pressure Overload. <i>JACC Basic To Translational Science</i> , 2020 , 5, 463-480	8.7	4
47	Safety and Feasibility of a Nocturnal Heart Rate Elevation-Exploration of a Novel Treatment Concept. <i>Journal of Cardiac Failure</i> , 2019 , 25, 67-71	3.3	4
46	Pathophysiology of Diastolic Heart Failure: Relaxation and Stiffness 2008 , 11-25		4
45	Changes in the crystallographic structures of cardiac myosin filaments detected by polarization-dependent second harmonic generation microscopy. <i>Biomedical Optics Express</i> , 2019 , 10, 3183-3195	3.5	4
44	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. <i>Circulation: Heart Failure</i> , 2021 , 14, e008052	7.6	4
43	Should We Test for Diastolic Dysfunction? How and How Often?. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 297-309	8.4	4
42	Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. <i>ESC Heart Failure</i> , 2021 , 8, 1706-1710	3.7	4
41	Neuromodulation device therapy for treatment of hypertensive heart disease. <i>Circulation Journal</i> , 2013 , 77, 1351-63	2.9	3
40	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
39	Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. <i>Journal of Cardiac Failure</i> , 2020 , 26, 876-884	3.3	3
38	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020 , 7, 3355	3.7	3
37	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1234-1248	6.1	3
36	The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice. <i>Human Molecular Genetics</i> , 2021 , 29, 3504-3515	5.6	3
35	Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?. <i>Heart Rhythm O2</i> , 2021 , 2, 37-45	1.5	3

34	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e019238	6	3
33	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 776-784	12.3	3
32	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e019545	6	3
31	Alterations in Ventricular Function 2011 , 213-231		2
30	Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 86-92	5.8	2
29	A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone. <i>Circulation</i> , 2021 , 144, 1269-1271	16.7	2
28	Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance. <i>ESC Heart Failure</i> , 2020 , 7, 3040-3048	3.7	2
27	Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2021 , 10, e018127	6	2
26	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 1346-1356	12.3	2
25	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007901	7.6	2
24	Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
23	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021 , 237, 45-53	4.9	2
22	Response to letters regarding article, "systolic and diastolic mechanics in stress cardiomyopathy". <i>Circulation</i> , 2015 , 131, e372	16.7	1
21	Response to Letter Regarding Article "Contractile Behavior of the Left Ventricle in Diastolic Heart Failure: With Emphasis on Regional Systolic Function" <i>Circulation</i> , 2006 , 114,	16.7	1
20	Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e022930	6	1
19	Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. <i>Clinical Cardiology</i> , 2020 , 43, 1501-1510	3.3	1
18	Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. <i>BMC Cardiovascular Disorders</i> , 2021 , 21, 155	2.3	1
17	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1334-1349	6.1	1

16	INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021 , 8, 849-860	3.7	1
15	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
14	The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.. <i>European Heart Journal</i> , 2022 ,	9.5	1
13	The Heart Failure Society of America in 2020: a vision for the future. <i>Journal of Cardiac Failure</i> , 2012 , 18, 90-3	3.3	0
12	Structural components of cardiomyocyte remodeling: summation. <i>Journal of Cardiac Failure</i> , 2002 , 8, S311-3	3.3	0
11	Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure.. <i>Journal of the American Heart Association</i> , 2022 , e024095	6	0
10	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6	0
9	Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF.. <i>PLoS ONE</i> , 2022 , 17, e0262479	3.7	0
8	Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. <i>American Journal of Medicine</i> , 2021 , 134, 797-804	2.4	0
7	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 336-346	7.9	0
6	Reply: Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2417-2418	15.1	
5	Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1535-6	15.1	
4	Assessment of Left Ventricular Diastolic Function in Mice. <i>Developments in Cardiovascular Medicine</i> , 2001 , 223-236		
3	Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1501-1502	15.1	
2	Pathophysiology of Heart Failure With a Preserved Ejection Fraction: Measurements and Mechanisms Causing Abnormal Diastolic Function 2021 , 11-30		
1	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1027-1030	3.3	